Skip to main content

COVID-19 Therapeutics

The FDA has given emergency use authorization to "Monoclonal Antibody Therapies" as a treatment option for COVID-19 positive patients, especially high-risk patients, with mild to moderate symptoms, but treatment needs to begin quickly after testing positive. Please ask your doctor more about this treatment if you are experiencing mild to moderate symptoms or have tested positive for COVID-19. This two-hour treatment may help boost your immune response and avoid time in the hospital.

Provider Resources

Council Oak Infusion Center, Tulsa

Council Oak, a Tulsa-based Hospital run by the Muscogee Creek Nation Department of Health, contains a 65-suite, monoclonal antibody infusion center. The infusion center will assist local health systems and providers in the fight against COVID-19. This public health initiative is a collaborative partnership with the Oklahoma State Department of Health (OSDH), Indian Health Service (IHS) and the Department of Health and Human Services (HHS) and will treat both Native and non-Native patients. Learn more:

Oklahoma Providers Dashboard